Citations

Clear

3138 citation(s) found for "Smith, AM".

“By the Skin of Our Teeth”: U.S. Hospital, Regional, and State Experiences of Scarcity During the COVID ‐19 Pandemic
Ennis, Jackson S. , Nguyen, Nicholas V. , Smith, Alexander K., Kramer, Daniel B. , Dp, Sulmasy, Tilburt, Jon C. , DeMartino, Erin S. , Smith, Alexander K. , Riggan, Kirsten A. , Nguyen, N.V. , Sulmasy, Daniel P.

Mayo Clinic

Journal of the American Geriatrics Society | January 20, 2026 | Volume: 74 | Issue: 3 | Pages: 729-737

10.1111/jgs.70300 | PMID 41556783 Get It

ABSTRACT Background The COVID‐19 pandemic presented unprecedented challenges to hospital system and critical care resources, leading to significant changes to operations and patient care. There are limited national data on these changes and instances of unsanctioned deviations from patient care, yet understanding the COVID response is key to future preparedness efforts. We sought to understand how hospitals and states navigated scarcity during COVID‐19, particularly in the absence of a declaration of crisis standards of care. Methods Between February 2022 and September 2022 we conducted 34 interviews with 36 leaders of U.S. states' COVID‐19 planning and response efforts. Interviews were transcribed verbatim and verified. We analyzed interviews using iterative inductive thematic analysis for descriptions of resource scarcity and changes to policies and procedures to prevent rationing lifesaving care. Results Nearly all participants described equipment and personnel scarcity in their home institution or state during COVID‐19. Hospitals across regions and states developed formal and informal coordination processes for load and resource sharing in response to influxes of high‐acuity patients, avoiding formal rationing of lifesaving resources in many regions. Participants also described unsanctioned patient triage, early discharge, and patients counseled to accept less aggressive care (e.g., premature transition to hospice) in states that had not declared crisis standards of care. Conclusions Extending limited resources and inter‐institutional collaboration helped avoid formal rationing. Yet, patient care was unquestionably impacted due to scarcity, both real and perceived. Reports of using hospital triage protocols to deny patients lifesaving care outside of formally recognized crisis conditions and attempts to nudge patients to accept less‐resource‐intensive care are concerning. This may have had disproportionate effects on older adults, individuals with disabilities, and racial and ethnic minoritized groups. To avoid unsanctioned deviations from standard practice in future health emergencies, we recommend that transparent and equitable triage protocols are implemented with robust oversight.
An externally validated machine learning model to predict cesarean surgical site infections
Lobel, Megan M. , Wagner, Stephen , Rivera‐Chiauzzi, Enid Y., Wyatt, Michelle A. , Pierce, Stephanie , Dyre, Lillian , Hamel, Maureen, Tuuli, Methodius G. , Lobel, Sam R., Smith, Megan , Rivera‐Chiauzzi, Enid Y. , Wagner, Stephen M , Rivera-Chiauzzi, Enid Y , Pierce, Stephanie L , Dyre, Lillian J

Mayo Clinic

Pregnancy | January 20, 2026 | Volume: 2 | Issue: 1 | Pages: No page available

10.1002/pmf2.70231 | PMID 42597018 Get It

Abstract Objective To develop a comprehensive risk stratification model to identify patients at high risk of cesarean surgical site infection (cSSI) based on information available at the time of hospital discharge. Methods This is a retrospective cohort study based on datasets from two independent level IV academic medical centers to improve generalizability. The first study includes 2336 cesarean deliveries for analysis with 109 instances of cSSI (4.7%). The second study includes 2936 cesarean deliveries with 72 instances of cSSI (2.5%). The first study cohort was utilized for both model training and internal validation, using the 15 shared features present in both datasets. Random search with cross‐validation was used to choose the type of machine learning (ML) model and its hyperparameters, with area under the receiver operating characteristic curve (AUC) as the validation metric. The second study cohort was then used to evaluate testing accuracy (external validation) and generalization capability of this model. The predictive importance of each feature was evaluated using permutation importance applied to the second cohort. Risk stratification cutoff scores were defined based on centiles over the first patient cohort and evaluated on the second cohort. Results The ML model with the highest validation AUC was an XGBoost classifier. This trained model achieved an AUC of 0.78 on the training data and a 0.72 cross‐validated AUC. When tested on data from the second study cohort, it achieved an AUC of 0.69. The features showing the strongest predictive generalization, as measured by permutation importance, were length of hospital stay, primary indication for cesarean delivery, and estimated blood loss. Using the second cohort to test our model, the model shows a 22.7% positive predictive value (PPV) of cSSI among women in the highest risk group, and a 0.8% PPV among women in the bottom risk group, compared with 2.5% cSSI incidence for the study population at large. Conclusion We developed and validated a predictive ML model for cSSI with information available to healthcare professionals at the time of hospital discharge. This model suggests that the most predictive risk factors for cSSI include length of hospital stay, primary indication for cesarean delivery, and estimated blood loss. Additionally, the model provides reasonable risk stratifications for individual patients. This tool may be used for identifying subgroups at higher risk of cSSI and identifying those who may require closer surveillance or clinical intervention.
Ocular Imaging in Intraocular Lymphoma: A Review
Ibrahim, Amin, Swaminathan, Vishal , Smith, Wendy M. , Swaminathan, Vishal B , Dalvin, Lauren A.

Mayo Clinic

Clinical & Experimental Ophthalmology | January 19, 2026 | Volume: 54 | Issue: 3 | Pages: 367-381

10.1111/ceo.70064 | PMID 41553010 Get It

ABSTRACT Intraocular lymphomas, including vitreoretinal and choroidal lymphoma, can simulate the clinical presentation of other benign and malignant ocular diseases resulting in diagnostic delays. Multimodal imaging features can raise early clinical suspicion to support appropriate subspecialty referrals and treatment for patients affected by these conditions. This review synthesises current evidence on the diagnostic and prognostic value of characteristic imaging features of these rare malignancies. Findings are reviewed based on imaging modality, including fundus photography, optical coherence tomography, fundus autofluorescence, fluorescein angiography, indocyanine green angiography, optical coherence tomography angiography, and ultrasound. We emphasise discriminative biomarkers that heighten suspicion for either vitreoretinal or choroidal lymphoma, as well as key findings to discriminate between lymphoma and alternative diagnoses. We further describe longitudinal changes in multimodal imaging features that can facilitate tracking disease progression or treatment response. By consolidating modality‐specific findings, this review aims to facilitate early referral and accurate diagnosis of these rare malignancies.
Optimizing Control Definitions in Opioid Use Disorder Genetic Research Using Electronic Health Records
Niarchou, Maria , Tsai, Ellen , Jennings, Mariela, Faucon, Annika, Lee, Hyunjoon, Tubbs, Justin D. , Roussos, Panos, Ge, Tian, Crist, Richard C. , Vickers‐Smith, Rachel, Edenberg, Howard, Moore, Amy, Webb, Bradley T. , Johnson, Eric, Workgroup, PsycheMERGE Substance Use Disorder, Smoller, Jordan W., Davis, Lea K., Coombes, BJ, Voloudakis, Georgios, Burstein, David , Mallard, TT, Troiani, Vanessa , Sanchez‐Roige, Sandra, Roussos, Panos , Johnson, Eric O. , Tsai, Ellen L , Tubbs, Justin D , Roussos, Panagiotis , Ge, Tian , Crist, Richard C , Vickers-Smith, Rachel , Moore, Amy , Johnson, Eric O , Kember, Rachel L , Voloudakis, Georgios , Burstein, David , Troiani, Vanessa , Sanchez-Roige, Sandra , Faucon, Annika B. , Singh, Kritika , Kember, Rachel L. , Smoller, Jordan W. , Davis, Lea Karatheodoris , Voloudakis, Georgios , Mallard, Travis T.

Mayo Clinic

Addiction Biology | January 19, 2026 | Volume: 31 | Issue: 1 | Pages: No page available

10.1111/adb.70094 | PMID 41549723 Get It

ABSTRACT Amidst the opioid crisis, understanding the genetic basis of opioid use disorder (OUD) is crucial for identifying biological mechanisms and intervention points. However, genome‐wide association studies (GWASs) have been hampered by inadequate sample sizes and often the use of control populations not assessed for prior opioid exposure. Because opioid exposure is a prerequisite for the development of OUD, consideration of exposure history in controls is important. Electronic health record data (EHR) paired with genomic information allow a broader sampling of patients with OUD and exposed controls. We leveraged data across two healthcare systems to evaluate the impact of using controls not screened for opioid exposure (‘generic’) versus minimally opioid‐exposed control (‘exposed’). First, at the phenotypic level, we conducted phenome‐wide association studies (PheWAS) to compare the medical comorbidity profiles of OUD cases when using generic versus exposed controls. While PheWAS results for OUD‐related comorbidities were more pronounced when using the generic group, 83% of the disease associations were overlapping and of similar effect sizes. Second, at the genetic level, we conducted GWAS (cases vs. generic; cases vs. exposed) and assessed differences in genetic correlations and degrees of phenotypic misclassification. Genetic results were concordant across control groups based on heritability (generic: 0.16 ± 0.07 vs. 0.10 ± 0.07), associations with the coding OPRM1 variant rs1799971 ( p generic = 8.83E‐03 vs. p exposed = 1.83E‐02) and genetic correlations with prior OUD GWAS ( r g‐generic = 0.83 ± 0.26 vs. r g‐exposed = 0.78 ± 0.27). Although GWASs were limited by sample size ( N generic = 6269, N exposed = 6365), compared to an independent OUD GWAS ( N = 425 944), the dilution value for the two GWAS was not different from 1, suggesting no major impact of phenotypic misclassification. This study represents the first effort to enhance OUD genetic research through optimization of control definitions using EHR data. Generic controls ascertained within the US health systems, where exposure to prescription opioids is high, offer a practical alternative for genetic studies of OUD.
Morphological characterization of a novel model of steatohepatitis in the FAH -/- pig
Wilken, Silvana, Minshew, Anna, Ahmadzada, Boyukkhanim , Hosseiniasl, Seyed M. , Kazeminia, Sara , Ezenekwe, Kachi, Patil, Ameya, Park, Byoung Uk , Sultan, Ahmer, Smith, L. Glenn, Correa, Julio Cisneros, Hussein, Kamal Hany , Moreira, Roger, Nyberg, Scott L. , Wilken, Silvana N , Felgendreff, Philipp , Kazeminia, Sara , Park, Byoung U , Cisneros Correa, Julio, Hussein, Kamal, Moreira, Roger K. , Nyberg, Scott L , Minshew, Anna, Ezenekwe, K., Patil, Ameya , Sultan, Ahmer, Smith, Lindsey, Hussein, Kamal Hany , Malhi, Harmeet

Mayo Clinic

Veterinary Pathology | January 17, 2026 | Volume: 63 | Issue: 4 | Pages: 746-756

10.1177/03009858251411305 | PMID 41546493 Get It

Metabolic dysfunction-associated steatohepatitis (MASH) is a global health care burden. Appropriate large animal models mimicking the main MASH characteristics of steatosis, inflammation, and hepatocyte damage alongside progression of fibrosis are imperative for robust preclinical studies, especially in the field of hepatobiliary surgery. The present study aimed to characterize a novel model of steatohepatitis in fumarylacetoacetate hydroxylase-deficient ( FAH -/- ) pigs. FAH -/- pigs were generated using a CRISPR/Cas9 system. The animals received a choline-deficient, L-amino acid-defined high-fat diet and subtherapeutic doses of nitisinone and were followed for 3 months. Liver biopsies were obtained at baseline and every month during treatment. Steatosis, inflammation, and fibrosis were assessed by conventional histological scoring systems and by an artificial intelligence (AI) model. Serum liver parameters were analyzed every 2 weeks. Steatosis increased significantly throughout the study, with severe steatosis observed as early as 2 months into treatment. The inflammation score was increased in all animals after 3 months of treatment, whereas the AI-based CD45+ cell count showed region-specific trends in the portal and lobular areas. Collagen content and the corresponding fibrosis stage showed an increase over the 3-month period; however, the difference was not significant. Serum liver parameters did not show any relevant elevations during the study. In summary, we successfully developed and characterized a novel model of steatohepatitis in the FAH -/- pig within 3 months. Further studies with prolonged observation time and/or cycling of nitisinone administration are needed to evaluate whether progressive fibrosis and cirrhosis could be achieved with this model.
MedMatch: a first step for the automation of large language model performance benchmarking for medication-related tasks
Blotske, Kaitlin , Zhao, Xingmeng , Cargile, Moriah , Tilley, Adeleine , Murray, Brian, Gao, Yanjun, Henry, Kelli , Smith, Susan E, Barreto, Erin, Bauer, Seth R. , Sohn, Sunghwan , Liu, Tianming, Smith, Susan , Murray, Brian , Henry, Kelli , Gao, Yanjun , Murray, Brian , Gao, Yanjun , Smith, Susan E , Frazee, Erin N , Bauer, Seth R , Liu, Tianming , Sikora, Andrea , Frazee, Erin N. , Blotske, Kaitlin , Zhao, Xingmeng

Mayo Clinic

No container title available | January 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.01.13.26343949 | PMID 41646690 Get It

Abstract Background The accuracy and safety of generating medication orders by large language models (LLMs) must be demonstrated. Without standardization, performance evaluation is limited to time and resource-intensive clinician grading. This evaluation aimed to develop a standardized medication format that supports automated performance evaluation (MedMatch). Methods First, a survey of 40 medication prompts was given to clinicians to assess agreement in medication order communication. Second, a clinician panel developed a standardized medication format (MedMatch) for oral and intravenous medications. Third, a clinician-annotated dataset of medication prompts and standardized answers in the MedMatch format was developed for LLM testing. Finally, LLMs were retested with the same dataset, adjusted to exclude route information, to evaluate the appropriate categorization of medication route. Results The formal medication orders consistently showed low omission rates and high overlap for all entities, compared to the verbal and brief written communication types. Lexical overlap results demonstrated pattern norms amongst clinicians with entities appearing most commonly in positions 1-5 in the order of drug name, dose, unit, route, and frequency. In the second survey, the formal written group performed the highest with 78.3% of prompts considered appropriate as a computer-generated response. LLM accuracy on MedMatch order standardization was highest in oral solid (64.2-72.5%), intravenous intermittent (72.5-84.3%), and intravenous push (62.7-74.5%) categories. LLMs performed the worst at categorizing medication orders accurately into intravenous push (18-61%) and intravenous intermittent (51-100%) routes. Conclusions Standardized format for computer-based outputs may support automated performance analysis and enhance the clarity of medication communication.
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET -Altered Solid Tumors: Analysis of the RETgistry Global Consortium
Waliany, Sarah , Cooper, Alissa J. , Liu, Stephen V. , Gautschi, O., Rotow, Julia K. , Smith, Katherine E. , Weber, Urs, Lee, Dae Ho , Loong, H., Patel, Jyoti D. , Nagasaka, Misako , Patel, Shetal , Tan, Daniel S. W., Solomon, Benjamin J., Pall, Georg , Riess, Jonathan W. , Sun, Lova , Früh, Martin, Uy, Natalie F., Gadgeel, Shirish, Feng, Jamie, Leighl, Natasha B., Baik, Christina S. , Lai, G., Ou, S. Ignatius, Cheung, Kingsley S.Y., Patil, Tejas, Weiler, Daniela , Yeap, Beow Y., Wirth, Lori J. , Gainor, Justin F., Drilon, Alexander D., Lin, Jessica J., Loong, Herbert H. , Rotow, Julia , Gautschi, Oliver , Smith, Katherine E R , Weber, Urs M , Loong, Herbert H , Pennell, Nathan A , Nagasaka, Misako , Patel, Shetal A , Tan, Daniel S W , Solomon, Benjamin J , Kim, Tae Min , Pall, Georg , Riess, Jonathan W , Sun, Lova , Früh, Martin , Uy, Natalie F , Gadgeel, Shirish , Feng, Jamie , Do, Andrew , Falcon, Christina , Leighl, Natasha B , Baik, Christina S , Lai, Gillianne G Y , Ou, Sai-Hong I , Cheung, Kingsley S Y , Patil, Tejas , Mansfield, Aaron S , Weiler, Daniela , Yeap, Beow Y , Wirth, Lori J , Gainor, Justin F , Drilon, Alexander , Lin, Jessica J , Liu, Stephen V , Früh, Martin , Gadgeel, Shirish M. , Feng, Jamie , Mansfield, Aaron S. , Gainor, Justin F.

Mayo Clinic

Clinical Cancer Research | January 15, 2026 | Volume: 32 | Issue: 6 | Pages: 1157-1168

10.1158/1078-0432.ccr-25-4382 | PMID 41537704 Get It

Abstract Purpose: Rearranged during transfection (RET) alterations are oncogenic drivers across solid tumors. Selective RET inhibitors (SRI) selpercatinib and pralsetinib have transformed outcomes for patients with RET-altered malignancies. Limited knowledge exists on genomic mechanisms of resistance to SRI. Experimental Design: We established “RETgistry,” a global consortium of patients with advanced RET-altered solid tumors who received SRI and underwent postprogression tissue or plasma biopsies assessed by next-generation sequencing. Frequencies of secondary RET resistance mutations and acquired non-RET gene alterations were determined. Progression-free survival (PFS) and time to treatment discontinuation (TTD) on first SRI were estimated with the Kaplan–Meier method. Results: RETgistry included 109 patients with RET-altered advanced solid tumors (lung, n = 94; thyroid, n = 15) who underwent 143 post-SRI progression biopsies (tissue, 91; plasma, 52). The median PFS and TTD were 13.9 months [95% confidence interval (CI), 10.1–16.6] and 17.3 months (95% CI, 14–20.2), respectively. Secondary RET mutations were detected in 20 (14%) biopsies [lung cancer, 15 (12.4%) and thyroid carcinoma, 5 (22.7%)]. Common acquired off-target alterations involved MET (18.2%; amplification, 15%), TP53 (8.2%), APC (7.6%), KRAS (7.1%), KEAP1 (5.9%), and CDKN2A/B (5.3%). MET alterations were enriched in post-SRI versus pre-SRI specimens (full cohort, 17.6% vs. 2.0%, P = 0.022; lung cancer, 19.1% vs. 2.1%, P = 0.022). Conclusions: The prevalence of secondary RET mutations after SRI was low, underscoring a greater role for off-target resistance. Recurrent acquired alterations involving tumor suppressor genes or upstream regulators of MAPK and PI3K pathways were identified, most commonly MET amplification. Continued efforts to characterize SRI resistance biology are critical to guide the development of novel therapeutic strategies.
Network Hypoactivity in ALG13-CDG: Disrupted Developmental Pathways and E/I Imbalance as Early Drivers of Neurological Features in CDG
Shah, Rameen , Budhraja, Rohit, Radenkovic, Silvia , Preston, Graeme , King, Alexia, Sabry, Sahar A. , Bleukx, Charlotte, Shammas, Ibrahim , Chandran, Jisha, Hrstka, Ronald F., Smith, Doughlas, Pandey, Akhilesh , Morava, Eva, Kozicz, T., Morava, Éva , Kozicz, Tamás , Hrstka, Ronald, Smith, Doughlas Y, Pandey, Akhilesh , Morava, Eva , Kozicz, Tamas , Preston, Graeme , Budhraja, Rohit , Sabry, Sahar, Young, Lyndsay E.A. , Byeon, Seul Kee , Staff, Nathan P. , Drake, Richard R. , Sloan, Steven A.

Mayo Clinic

Cells | January 14, 2026 | Volume: 15 | Issue: 2 | Pages: 147

10.3390/cells15020147 | PMID 41597222 Get It

Background: ALG13-CDG is an X-linked N-linked glycosylation disorder caused by pathogenic variants in the glycosyltransferase ALG13, leading to severe neurological manifestations. Despite the clear CNS involvement, the impact of ALG13 dysfunction on human brain glycosylation and neurodevelopment remains unknown. We hypothesize that ALG13-CDG causes brain-specific hypoglycosylation that disrupts neurodevelopmental pathways and contributes directly to cortical network dysfunction. Methods: We generated iPSC-derived human cortical organoids (hCOs) from individuals with ALG13-CDG to define the impact of hypoglycosylation on cortical development and function. Electrophysiological activity was assessed using MEA recordings and integrated with multiomic profiling, including scRNA-seq, proteomics, glycoproteomics, N-glycan imaging, lipidomics, and metabolomics. X-inactivation status was evaluated in both iPSCs and hCOs. Results: ALG13-CDG hCOs showed reduced glycosylation of proteins involved in ECM organization, neuronal migration, lipid metabolism, calcium homeostasis, and neuronal excitability. These pathway disruptions were supported by proteomic and scRNA-seq data and included altered intercellular communication. Trajectory analyses revealed mistimed neuronal maturation with early inhibitory and delayed excitatory development, indicating an E/I imbalance. MEA recordings demonstrated early network hypoactivity with reduced firing rates, immature burst structure, and shortened axonal projections, while transcriptomic and proteomic signatures suggested emerging hyperexcitability. Altered lipid and GlcNAc metabolism, along with skewed X-inactivation, were also observed. Conclusions: Our study reveals that ALG13-CDG is a disorder of brain-specific hypoglycosylation that disrupts key neurodevelopmental pathways and destabilizes cortical network function. Through integrated multiomic and functional analyses, we identify early network hypoactivity, mistimed neuronal maturation, and evolving E/I imbalance that progresses to compensatory hyperexcitability, providing a mechanistic basis for seizure vulnerability. These findings redefine ALG13-CDG as disorders of cortical network instability, offering a new framework for targeted therapeutic intervention.
Drug or Pokémon? Large language model performance in identification of fabricated medications
Henry, Kelli , Murray, Brian, Zhao, Xingmeng , Blotske, Kaitlin , Gao, Yanjun, Smith, Brooke, Smith, Susan , Barreto, Erin, Bauer, Seth R. , Sohn, Sunghwan , Liu, Tianming , Cohen, Mitch, Abdulnour, Raja-Elie E, Le, Khoa , Zhou, Hongjian , Clifton, David A. , Murray, Brian , Henry, Kelli , Gao, Yanjun , Smith, Brooke , Murray, Brian , Gao, Yanjun , Smith, Susan E , Frazee, Erin N , Bauer, Seth R , Bennett, Tell , Cohen, Mitch , Abdulnour, Raja-Elie E , Sikora, Andrea , Sohn, Sunghwan , Frazee, Erin N. , Celi, Leo Anthony , Liu, Fenglin , Blotske, Kaitlin , Zhao, Xingmeng

Mayo Clinic

No container title available | January 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.01.12.26343930 | PMID 41646757 Get It

Abstract Background Large language models (LLMs) are increasingly used in medication-related tasks despite limited evidence supporting their accuracy and safety. LLMs are vulnerable to adversarial attacks and may confabulate in response to fabricated information in the prompt. Given the substantial risk of harm from medication errors, the purpose of this study was to establish a benchmark task to evaluate LLM performance in distinguishing fabricated from real medications. Methods Two datasets (brand and generic), each consisting of 250 medication lists were developed, each including 4-6 medications and one fabricated medication (specifically a Pokémon character), with complete dosing information provided. Six LLMs were evaluated (GPT-5-Chat, GPT-4o-mini, DrugGPT, Gemma-3-27B-IT, Llama-3.3-70B-Instruct, and Qwen3-32B). For each medication list, models were queried for dosing information and disease indication across three experimental conditions: standard decoding, standard decoding with mitigation prompting, and deterministic decoding (temperature = 0). Each experiment was performed in triplicate. Outputs were deemed confabulations if the LLM failed to recognize and reject the fabricated medication. The primary outcome was the rate of confabulations. Exact paired-permutation tests were used to compare confabulation rates across LLMs and prompting approaches. Results Confabulation rates under standard conditions ranged from 2.7% to 99.6%. DrugGPT demonstrated the lowest baseline confabulation rates (2.7-6.4%), whereas other models demonstrated substantially higher rates (47.2-99.6%). Mitigation prompting significantly reduced confabulation rates compared to standard and deterministic decoding across all tasks and datasets (p < 0.001): GPT-5-Chat achieved confabulation rates of 0% with mitigation prompting from baseline rates of 66.4-88.5%. Deterministic decoding did not substantially impact confabulation rates. Conclusions LLMs performing medication-related tasks are susceptible to confabulation in response to invalid or fabricated inputs, raising important safety concerns for clinical use. While mitigation prompting reduced confabulation rates, this study underscores the importance of robust safeguards when deploying LLMs in medication-related decision-making.
Mutational analysis and identification of potential biomarkers in patients with metastatic pancreatic cancer treated with the combination of the GSK-3 inhibitor elraglusib and gemcitabine/nab-paclitaxel in the 1801 Part 3B phase 2 study.
Shroff, Rachna T. , Carneiro, Benedito A. , Cervantes, Andres, Sahai, Vaibhav , Ploquin, Anne , Hiret, Sandrine , Lopez, Charles D., Pernot, S., Kaván, Petr, Mulcahy, Mary Frances, Smith, Sheri , Jaros, Mark, Bekaii-Saab, Tanios S., Mazar, Andrew P. , Sahai, Vaibhav , Ugolkov, Andrey , Mahalingam, Devalingam , Coveler, Andrew L. , Cervantes, Andrés , LoConte, Noelle K. , Lopez, Charles D. , Pernot, Simon , Mulcahy, Mary F. , Carr, Ryan M , Giles, Francis Joseph , Bekaii‐Saab, Tanios

Mayo Clinic

Journal of Clinical Oncology | January 12, 2026 | Volume: 44 | Issue: 2_suppl | Pages: 761-761

10.1200/jco.2026.44.2_suppl.761 Get It

761 Background: Glycogen Synthase Kinase-3β (GSK-3β) is a known therapeutic target in cancer including pancreatic adenocarcinoma (PDAC). The combination of elraglusib (9-ING-41), a novel GSK-3 inhibitor, and gemcitabine/nab-paclitaxel (GnP) is being evaluated as first-line therapy for patients with metastatic PDAC (mPDAC). We previously reported topline results indicating that the 1801 Part 3B phase 2 trial (NCT03678883) met its primary endpoint, showing a clinically meaningful survival benefit in patients treated with elraglusib/GnP compared to GnP alone. Here, we examined whether gene mutations correlated with clinical outcomes in mPDAC patients enrolled in this randomized phase 2 trial. Methods: For mutational analysis, archival tumor and/or plasma samples were obtained from 53 (GnP group) and 117 (elraglusib/GnP group) patients with previously untreated mPDAC. Cell-free DNA and/or tumor-extracted DNA were analyzed using the next generation sequencing. The comparison of the response rates was performed with the use of Chi-square tests. Kaplan-Meier survival curves were compared by log-rank (Mantel-Cox) tests. Results: Mutational analysis identified frequently mutated genes (detectable in ≥25% of patients): KRAS (141/170, 83%), TP53 (121/170, 71%), and CDKN2A (56/170, 33%). Mutations in KRAS, TP53, or CDKN2A genes did not correlate with objective response rate. Based on 81% of the recorded death events in the elraglusib/GnP group and 91% in the GnP group (topline data April, 2025), KRAS and TP53 gene mutations were associated with worse overall survival (OS) in patients treated with elraglusib/GnP (p<0.05) but not in GnP-treated patients. The rate of triple (KRAS+TP53+CDKN2A) mutations was significantly higher in the patients with OS<2 months as compared to the patients with OS>2 months in the elraglusib/GnP group (p<0.05) but not in the GnP group. Conclusions: Our preliminary results identified KRAS and TP53 gene mutations as potential predictive biomarkers of clinical outcome in elraglusib/GnP-treated mPDAC patients. Updated OS data and mutational analysis will be included in the final presentation. Clinical trial information: NCT03678883 .